BMS delays Alzheimer’s psychosis data to protect scientific rigor despite strong earnings
Delaying a pivotal trial readout despite strong financial performance shows a deliberate choice to prioritize data quality and scientific confidence over short-term market expectations, reinforcing the principle that product validation timing must align with robust evidence rather than external pressures.
Bristol Myers Squibb postponed the phase 3 data readout for its Alzheimer’s psychosis drug Cobenfy from 2026 to early 2027, spreading the releases across the year. This delay occurred even as BMS beat quarterly revenue estimates and raised its full-year guidance, signaling confidence in its broader portfolio.